Phase 1 Neoplasms Clinical Trials
122 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 122 trials
Recruiting
Phase 1
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
Solid TumorsNeoplasms
National Cancer Institute (NCI)65 enrolled1 locationNCT03366116
Recruiting
Phase 1
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Myelofibrosis (MF)Polycythemia Vera (PV)Myeloproliferative Neoplasms (MPNs)
Prelude Therapeutics100 enrolled1 locationNCT07469891
Recruiting
Phase 1Phase 2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled50 locationsNCT06469944
Recruiting
Phase 1Phase 2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled44 locationsNCT06445972
Recruiting
Phase 1
A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Boehringer Ingelheim300 enrolled12 locationsNCT04429087
Recruiting
Phase 1
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Neuroendocrine Neoplasms
Boehringer Ingelheim55 enrolled19 locationsNCT06132113
Recruiting
Phase 1
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Hematologic NeoplasmsHematologic Malignancies
National Cancer Institute (NCI)155 enrolled1 locationNCT07162038
Recruiting
Phase 1Phase 2
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Hematologic Neoplasms
National Cancer Institute (NCI)430 enrolled1 locationNCT05327023
Recruiting
Phase 1Phase 2
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Hematologic Neoplasms
National Cancer Institute (NCI)320 enrolled2 locationsNCT04959175
Recruiting
Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 1
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Urothelial CancerBladder CancerGenitourinary Cancer+2 more
National Cancer Institute (NCI)100 enrolled1 locationNCT04235777
Recruiting
Phase 1Phase 2
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled18 locationsNCT06785636
Recruiting
Phase 1Phase 2
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Urinary Bladder NeoplasmsBladder Cancer
Merck Sharp & Dohme LLC45 enrolled14 locationsNCT07222488
Recruiting
Phase 1Phase 2
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Neoplasms, Prostate
GlaxoSmithKline54 enrolled6 locationsNCT07332455
Recruiting
Phase 1Phase 2
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Neoplasms, Prostate
GlaxoSmithKline85 enrolled15 locationsNCT06990880
Recruiting
Phase 1Phase 2
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Breast CancerBreast Neoplasms
Pfizer100 enrolled166 locationsNCT06966453
Recruiting
Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer914 enrolled44 locationsNCT06131840
Recruiting
Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company535 enrolled84 locationsNCT05614739
Recruiting
Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled158 locationsNCT04389632